N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

US7807683B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Timothy J. Guzi · Chatham, US
• Kamil Paruch · Garwood, US
• Michael P. Dwyer · Scotch Plains, US
• Ronald J. Doll · Maplewood, US
• Viyyoor M. Girijavallabhan · Parsippany, US
• Alan K. Mallams · Hackettstown, US
• Carmen Alvarez · Roselle Park, US
• Kartik M. Keertikar · Plainsboro, US
• Jocelyn Rivera · Monmouth Junction, US
• Tin-Yau Chan · Edison, US
• Vincent S. Madison · Mountain Lakes, US
• Thierry O. Fischmann · Scotch Plains, US
• Lawrence Wayne Dillard · Yardley, US
• Vinh D. Tran · Willow View Lane, US
• Zhen Min He · Princeton, US
• Ray Anthony James · Bristol, US
• Haengsoon Park · Plainsboro, US
• Vidyadhar Paradkar · Somerville, US
• Douglas W. Hobbs · Yardley, US

Key dates

• Filing date: Mar 31, 2006
• Grant date: Oct 5, 2010
• Expiry date: Dec 24, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.